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analyses of DALYs could enrich our understanding of the
interaction between approaches to testicular cancer care and
patient experience. For example, Pishgar et al. [4] report that
Kiribati, Chile, and Argentina had the highest testicular
cancer-speciﬁc age-standardised DALY rates. Focussed
qualitative research in these countries, possibly incorporating
comparisons with higher performing settings, could facilitate
targeted improvements to patient care and experience. As
more countries achieve the highest cure rates for testicular
cancer, patient experience will assume increasing importance
as a measure of care quality in this disease.
Analyses like this have the potential to provoke important
conversations and to generate hypotheses in specialist clinical
and health policy research. As clinicians, researchers and
policy-makers, this study should encourage us to think
critically about the policy context in which we see testicular
cancer, the reasons patients might present late, and how
equity of outcome might be achieved both within and beyond
our own immediate surroundings. Pishgar et al. [4]
invaluably remind us that we remain some way off being able
to call testicular cancer a curable disease for all patients, in all
settings.
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Flares of chronic pelvic pain syndrome: lessons
learned from the MAPP Research Network
Chronic pelvic pain syndrome (CPPS) is one of the
unresolved problems in urology. There are multiple
recommendations for the management of CPPS, and the BJUI
guideline of guidelines on bladder pain syndrome by Malde
et al. [1] summarizes differences in nomenclature, deﬁnitions
and recommended diagnostic tests and treatments between
major national and international guidelines. CPPS is deﬁned
according to the European Association of Urology as chronic
or persistent pain perceived in structures related to the pelvis
without proven infection or other obvious local pathology
that may account for the pain, and it is often associated with
negative cognitive, behavioural, sexual and emotional
consequences, as well as with symptoms suggestive of lower
urinary tract, sexual, bowel, pelvic ﬂoor or gynaecological
dysfunction [2]. Despite exacerbations of CPPS symptoms,
so-called ‘ﬂares’ (i.e. sudden appearance or worsening of
symptoms) that highly affect the patients’ quality of life and
strongly challenge their treating physicians, relevant
characteristics of CPPS such as frequency, intensity, duration
and risk factors are largely unknown.
In this month’s issue of the BJUI, Sutcliffe et al. [3] bring
light into this darkness and present their ﬁndings from the
Multidisciplinary Approach to the Study of Chronic Pelvic
Pain (MAPP) Research Network. A total of 385 participants
were eligible for participation in their 1-year, multi-site
longitudinal study. Symptom ﬂares were very common, with
approximately three-quarters of the sample reporting at least
one ﬂare (23% reported one ﬂare, 28% two to three ﬂares and
25% four or more ﬂares), ﬂare duration ranged widely from 1
to 150 days, and variability in symptoms, frequency, and
duration was very relevant both between and within
participants. Risk factors for greater ﬂare burden (greater ﬂare
frequency, symptom intensity and/or duration) were female
gender, worse non-ﬂare symptoms and bladder
hypersensitivity or chronic overlapping pain conditions. These
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new insights into the characteristics of CPPS close several
gaps in our knowledge, but also raise many questions. What
are the reasons that one-quarter of patients with CPPS did
not experience ﬂares and what can we learn from this speciﬁc
subgroup to optimize our treatment strategies? What are the
pathomechanisms involved? Can we use biomarkers to
identify patients at risk of CPPS ﬂares? Would there be
protective factors to obviate CPPS ﬂares? How can we
optimize the management of CPPS ﬂares to improve the
quality of life of affected patients? Despite these many
questions, there is light at the end of the tunnel: the
aforementioned MAPP Research Network (www.mappne
twork.org). This network, established by the National Institute
of Diabetes and Digestive and Kidney Diseases of the
National Institutes of Health in 2008, is a whole-body
initiative which has enormously expanded our knowledge in
the ﬁeld of CPPS in recent years. Such research networks,
unifying highly multidisciplinary approaches through the
collaboration of scientists, epidemiologists and clinicians, are
essential to push the borders of knowledge, paving the way
for novel management strategies. Together we are strong,
with basic and clinical research linked by translation and
reverse translation enabling innovations and ﬁnally resulting
in better patient care. However, although a customized,
patient-tailored bio-psycho-social approach engaging the
patient in a collaborative journey towards self-management is
strongly recommended and generally accepted for CPPS [4],
ﬂares remain a major issue. We still have to solve this
Gordian knot; however, per aspera ad astra! The next steps
are to prevent ﬂares and to ﬁnd an optimal ﬂare treatment.
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Non-invasive diagnosis and monitoring of
urothelial bladder cancer: are we there yet?
In this issue of BJUI, Ward et al. [1] describe the
development of DNA-based urinary biomarkers for urothelial
carcinoma (UC). The genomics of UC have been well
characterized through interrogation of tumour issues in
institutional series (e.g. the Memorial Sloan Kettering Cancer
Center [MSKCC] experience), multi-institutional
collaborations (e.g. The Cancer Genome Atlas [TCGA]) and
commercial platforms (e.g. the Foundation Medicine
experience) [2]. Until recently, these have been largely
academic pursuits, with possible impact on prognostication
but limited clinical applicability and utility for therapy
selection and monitoring of response; however, with the US
Food and Drug Administration approval of erdaﬁtinib several
weeks ago, patients with advanced UC will routinely receive
genomic assessment for FGFR2/3 mutation or fusion, the
targets for this therapy [3]. In due time, it is anticipated that
multiple other putative targets with associated therapies (e.g.
ERBB2, CDKN2A), as well as potential predictive biomarkers,
may also warrant testing.
The evolving landscape in advanced UC makes a non-
invasive biomarker particularly attractive. The authors of the
present commentary have previously reported results from a
series of 369 patients with advanced UC, demonstrating that
genomic alterations in ctDNA could be identiﬁed in 91% of
patients using a commercially available 73 gene panel [4].
More recently, Christensen et al. [5] assessed a cohort of 68
patients receiving neoadjuvant chemotherapy for muscle-
invasive disease, demonstrating 100% sensitivity and 98%
speciﬁcity for the detection of relapsed disease with a patient-
speciﬁc ctDNA assessment (sequenced to a median target
coverage of 105 0009) after cystectomy. Impressively, the
data also showed that the dynamics of ctDNA appeared to be
more useful than pathological downstaging in predicting
relapse.
In contrast to these studies, Ward et al. have developed a 23-
gene panel based on frequently expressed genes in a cohort of
916 UC tissue specimens, largely derived from patients with
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